Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > GUD trading at fair value?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(37)
•••
Comment by wagyusteakon Jan 12, 2021 7:10pm
160 Views
Post# 32281685

RE:RE:RE:GUD trading at fair value?

RE:RE:RE:GUD trading at fair value?

EbbFlow88 wrote: I guess that depends on what you think the future is for the BRL.It is historically cheap now. Will that continue or revert to the mean?

If you believe that GUD bought it cheap, well now its very cheap. 

If you have a long-term view, then it is likely it will rebound, GBT will grow and GUD will make more acquisitions. Maybe I'm wrong but odds seem in our favor here.

 

you can't explain reasons to a knucklehead bro. We tried, it didn't work. Just talk stock price to him. He understands it. Up means good, down means bad. Lol

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities